[Retracted] Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World

Table 5

PD-L1 detection techniques for different immunotherapy agents.

Drug	Mechanism	Company	PD-L1 detection technology	Thresholds in clinical studies
Atezolizumab	PD-L1	Roche	Ventana PD-L1 (SP142) assay	TC0/1/2/3 or IC0/1/2/3
Avelumab	PD-L1	EMD	Without testing	1% or higher
Durvalumab	PD-L1	AstraZeneca	Ventana PD-L1 (SP263) assay	25% or higher
Pembrolizumab	PD-1	Merck	Dako PD-L1 IHC 22CS pharmDx	1% or 50% or higher
Nivolumab	PD-1	BMS	Dako PD-L1 IHC 28-8 pharmDx	≥1% or ≥5% or ≥10%